ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $15.7 million in its second quarter.
The St. Helier, Jersey-based company said it had a loss of 13 cents per share.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 30 cents per share.
The oncology drug developer posted revenue of $183.6 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $174.1 million.
NovoCure expects full-year revenue in the range of $710 million to $725 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
